Literature DB >> 16788150

Slow start to phase 0 as researchers debate value.

Renee Twombly.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16788150     DOI： 10.1093/jnci/djj249

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Advances in cancer therapeutics.

Authors:  A Sparreboom; J Verweij
Journal:  Clin Pharmacol Ther       Date:  2009-02       Impact factor: 6.875

2.  Phase 0 clinical trials in oncology new drug development.

Authors:  Umesh Chandra Gupta; Sandeep Bhatia; Amit Garg; Amit Sharma; Vaibhav Choudhary
Journal:  Perspect Clin Res       Date:  2011-01

3.  IDEAL-D Framework for Device Innovation: A Consensus Statement on the Preclinical Stage.

Authors:  Hani J Marcus; Amy Bennett; Aswin Chari; Toni Day; Allison Hirst; Archie Hughes-Hallett; Angelos Kolias; Richard M Kwasnicki; Janet Martin; Maroeska Rovers; Sarah E Squire; Peter McCulloch
Journal:  Ann Surg       Date:  2022-01-01       Impact factor: 13.787

Review 4.  The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.

Authors:  S Marchetti; J H M Schellens
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.